AZD1480

製品コード：S2162 純度：99.16%

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.

CAS No. 935666-88-9

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
5mg	JPY 22000	国内在庫あり
50mg	JPY 85500	国内在庫あり
200mg	JPY 235500	国内在庫なし(納期7~10日)
1g	JPY 745500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（117）

製品安全説明書

現在のバッチを見る：純度： 99.16%

99.16

AZD1480関連製品

関連ターゲット	JAK1 JAK2 JAK3 Tyk2	もっと見る
関連製品	WP1066 Momelotinib (CYT387) Filgotinib (GLPG0634) AT9283 Gandotinib (LY2784544) TG101209 Cerdulatinib (PRT062070) hydrochloride Pacritinib NVP-BSK805 2HCl WHI-P154 FLLL32 Decernotinib (VX-509) CEP-33779 AZ 960 Cerdulatinib (PRT062070) ZM 39923 HCl XL019 BMS-911543 Curcumol Solcitinib Oclacitinib maleate Pyridone 6 Creatine Ritlecitinib (PF-06651600) Deucravacitinib (BMS-986165) Itacitinib (INCB39110) Peficitinib BD750 WHI-P97 JANEX-1 Brevilin A 1,2,3,4,5,6-Hexabromocyclohexane Brepocitinib (PF-06700841) FM-381 SAR-20347 Selective JAK3 inhibitor 1	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Tyrosine Kinase Inhibitor Library JAK/STAT compound library	もっと見る

シグナル伝達経路

JAKシグナル伝達経路

JAK阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
NCI-H82	Apoptosis Assay	0.3/1/3 μM	48 h	increases the level of cleaved-Caspase 3	24158701
GLC4	Apoptosis Assay	0.3/1/3 μM	48 h	increases the level of cleaved-Caspase 3	24158701
NCI-N592	Apoptosis Assay	0.3/1/3 μM	48 h	increases the level of cleaved-Caspase 3	24158701
NCI-H82	Function Assay	0.3/1/3 μM	24 h	induces G2/M cell cycle arrest	24158701
GLC4	Function Assay	0.3/1/3 μM	24 h	induces G2/M cell cycle arrest	24158701
NCI-N592	Function Assay	0.3/1/3 μM	24 h	induces G2/M cell cycle arrest	24158701
CWR22Rv1	Function Assay	800 nM	72 h	suppresses IL-6-induced migratory	24577942
DU145	Function Assay	800 nM	72 h	suppresses IL-6-induced migratory	24577942
DU145	Function Assay	0-200 nM	1 h	suppresses IL-6-activated Stat3 and ERK1/2 signaling	24577942
MO4	Function Assay	0.5/1/5 μM	6 h	inhibits P-STAT3 expression	25149535
OVCAR-8	Apoptosis Assay	0.5/1/5 μM	48 h	induces significant apoptosis at high concerntration	25646015
OVCAR-5	Apoptosis Assay	0.5/1/5 μM	48 h	induces significant apoptosis at high concerntration	25646015
OVCAR-8	Cell Viability Assay	0.05-10 μM	72 h	reduces cell viability at the concerntration of 5 μM	25646015
OVCAR-5	Cell Viability Assay	0.05-10 μM	72 h	reduces cell viability at the concerntration of 5 μM	25646015
A1847	Cell Viability Assay	0.05-10 μM	72 h	reduces cell viability at the concerntration of 5 μM	25646015
MOVCAR-5009	Function Assay	0.05-10 μM	24 h	reduces phosphorylated STAT3 levels	25646015
MOVCAR-5447	Function Assay	0.05-10 μM	24 h	reduces phosphorylated STAT3 levels	25646015
OVCAR-8	Function Assay	0.05-10 μM	24 h	reduces phosphorylated STAT3 levels	25646015
OVCAR-5	Function Assay	0.05-10 μM	24 h	reduces phosphorylated STAT3 levels	25646015
A1847	Function Assay	0.05-10 μM	24 h	reduces phosphorylated STAT3 levels	25646015
UM-22A	Function Assay	0.0005-1.6 μM	24 h	abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
HH5	Function Assay	0.0005-3.8 μM	24 h	abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
Cal33	Function Assay	0.0005-3.8 μM	24 h	abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
UMSCC-1	Function Assay	0.0005-1.6 μM	24 h	abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner	25810010
LoVo	Function Assay	5 μM	48 h	blocks JAK2/STAT3 signaling	25954974
SW620	Function Assay	5 μM	48 h	blocks JAK2/STAT3 signaling	25954974
KCNR	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	induces an increase in caspase 3/7 activity	23531921
SY5Y	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	induces an increase in caspase 3/7 activity	23531921
Rh18	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	induces an increase in caspase 3/7 activity	23531921
TC32	Apoptosis Assay	0.5/1.0/2.5 μM	24 h	induces an increase in caspase 3/7 activity	23531921
KCNR	Function Assay	0.5/1.0/2.5/5 μM	24 h	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
SY5Y	Function Assay	0.5/1.0/2.5/5 μM	24 h	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
Rh18	Function Assay	0.5/1.0/2.5/5 μM	24 h	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
TC32	Function Assay	0.5/1.0/2.5/5 μM	24 h	inhibits both endogenous constitutive and IL-6-induced STAT3 activation	23531921
TPC-1	Growth Inhibition Assay	1 µM	0-4 d	inhibits cell growth after 2 d treatment	23056499
MZ-CRC1	Growth Inhibition Assay	1 µM	0-5 d	inhibits cell growth after 1 d treatment	23056499
TT	Growth Inhibition Assay	1 µM	0-4 d	inhibits cell growth after 1 d treatment	23056499
TPC-1	Function Assay	1 µM	72 h	induces G1 blockage	23056499
MZ-CRC1	Function Assay	1 µM	72 h	induces G1 blockage	23056499
TT	Function Assay	1 µM	72 h	induces G1 blockage	23056499
MZ-CRC1	Apoptosis Assay	1 µM	48 h	induces apoptosis	23056499
TT	Apoptosis Assay	1 µM	48 h	induces apoptosis	23056499
HD-LM2	Function Assay	0.1/0.5/1/5 μM	72 h	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
L-428	Function Assay	0.1/0.5/1/5 μM	72 h	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
KM-H2	Function Assay	0.1/0.5/1/5 μM	72 h	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
L-540	Function Assay	0.1/0.5/1/5 μM	72 h	inhibits STAT3, STAT5 and STAT6 phosphorylation	22829094
HD-LM2	Apoptosis Assay	1/5 μM	72 h	induces apoptosis	22829094
L-428	Apoptosis Assay	1/5 μM	72 h	induces apoptosis	22829094
KM-H2	Apoptosis Assay	1/5 μM	72 h	induces apoptosis	22829094
L-540	Apoptosis Assay	1/5 μM	72 h	induces apoptosis	22829094
U251-MG	Function Assay	1 µM	0-16 h	inhibits constitutive STAT-3 and JAK2 activation	22027691
U87-MG	Function Assay	1 µM	0-16 h	inhibits constitutive STAT-3 and JAK2 activation	22027691
4C8	Function Assay	1 µM	0-16 h	inhibits constitutive STAT-3 and JAK2 activation	22027691
U251-MG	Growth Inhibition Assay	1/10 µM	24/48/72 h	inhibits cell proliferation at a concentration of 10 µM	22027691
U87-MG	Growth Inhibition Assay	1/10 µM	24/48/72 h	inhibits cell proliferation at a concentration of 10 µM	22027691
4C8	Growth Inhibition Assay	1/10 µM	24/48/72 h	inhibits cell proliferation at a concentration of 10 µM	22027691
U266	Apoptosis Assay	0.5-2 μM	48/72 h	induces apoptosis dose dependently	21164517
Kms.11	Apoptosis Assay	0.5-2 μM	48/72 h	induces apoptosis dose dependently	21164517
8226	Apoptosis Assay	0.5-2 μM	48/72 h	induces apoptosis dose dependently	21164517
SW620	Cell cycle assay	3.3 uM	24 hrs	Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase at 3.3 uM after 24 hrs by flow cytometry	21138246
HEL	Function assay	0.3 uM	5 mins	Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting	21138246
HEL	Function assay	0.3 uM	30 to 60 mins	Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting	21138246
BA/F3	Antitumor assay	30 mg/kg	12 hrs	Antitumor activity against mouse BA/F3 cells expressing Tel-JAK2 xenografted in NCr mouse assessed as reduction of phosphorylated Stat5 level in spleen at 30 mg/kg, po after 12 hrs by Western blotting	21138246
HEL	Function assay	0.3 uM	5 mins	Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting	21138246
HEL	Function assay	0.3 uM	30 to 60 mins	Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting	21138246
Hs578T	Function assay	1 uM	24 hrs	Inhibition of STAT3C-mediated transcription in human Hs578T cells at 1 uM after 24 hrs by luciferase reporter gene assay	24978112
NCI-H1975	Function assay	0.003 to 3 uM	2 hrs	Inhibition of JAK1 in human NCI-H1975 cells assessed as reduction in STAT3 phosphorylation at 0.003 to 3 uM after 2 hrs by Western blot analysis	26614408
PALJDL	Cell Viability Assay		72 h	IC50=2.4 μM	25504635
AKRSL	Cell Viability Assay		72 h	IC50＞10 μM	25504635
PCI-15B	Growth Inhibition Assay		72 h	EC50=0.99 ± 1.74 μM	25810010
PCI-52	Growth Inhibition Assay		72 h	EC50=1.00 ± 0.09 μM	25810010
OSC19	Growth Inhibition Assay		72 h	EC50=1.26 ± 0.20 μM	25810010
UM-22A	Growth Inhibition Assay		72 h	EC50=1.32 ± 0.39 μM	25810010
UM SCC-1	Growth Inhibition Assay		72 h	EC50=1.67 ± 0.42 μM	25810010
686LN	Growth Inhibition Assay		72 h	EC50=2.05 ± 1.33 μM	25810010
UM-22B	Growth Inhibition Assay		72 h	EC50=2.66 ± 0.24 μM	25810010
Cal33	Growth Inhibition Assay		72 h	EC50=3.37 ± 0.75 μM	25810010
HN5	Growth Inhibition Assay		72 h	EC50=3.81 ± 1.99 μM	25810010
HD-LM2	Growth Inhibition Assay		72 h	IC50=7.844 μM	22829094
L-428	Growth Inhibition Assay		72 h	IC50=7.947 μM	22829094
KM-H2	Growth Inhibition Assay		72 h	IC50=1.308 μM	22829094
L-540	Growth Inhibition Assay		72 h	IC50=8.216 μM	22829094
SET2	Growth inhibition assay		48 hrs	Growth inhibition of human SET2 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.016 μM.	21138246
SET2	Function assay		1 hr	Inhibition of Stat3 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.023 μM.	21138246
SET2	Function assay		1 hr	Inhibition of Stat5 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.025 μM.	21138246
HEL	Function assay		1 hr	Inhibition of Stat5 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.041 μM.	21138246
UKE1	Growth inhibition assay		48 hrs	Growth inhibition of human UKE1 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.054 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs	Growth inhibition of mouse BA/F3 cells expressing Tel-JAK2 kinase after 48 hrs by MTS assay, GI50 = 0.06 μM.	21138246
HEL	Function assay		1 hr	Inhibition of Stat3 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.08 μM.	21138246
HEL	Growth inhibition assay		48 hrs	Growth inhibition of human HEL cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.39 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs	Growth inhibition of mouse BA/F3 cells expressing Tel-JAK1 kinase after 48 hrs by MTS assay, GI50 = 0.7 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs	Growth inhibition of mouse BA/F3 cells expressing Tel-Tyk2 kinase after 48 hrs by MTS assay, GI50 = 2 μM.	21138246
BA/F3	Growth inhibition assay		48 hrs	Growth inhibition of mouse BA/F3 cells expressing Tel-JAK3 kinase after 48 hrs by MTS assay, GI50 = 2.1 μM.	21138246
UKE1	Function assay		1 hr	Inhibition of Stat5 phosphorylation in human UKE1 cells after 1 hr by Western blotting	21138246
HEL 92.1.7	Function assay		2 hrs	Inhibition of JAK2 in human HEL 92.1.7 cells assessed as reduction in STAT5 phosphorylation after 2 hrs by Western blot analysis	26614408
IMR32	Growth Inhibition Assay			IC50=0.66 μM	23531921
NGP	Growth Inhibition Assay			IC50=0.56 μM	23531921
AS	Growth Inhibition Assay			IC50=1.53 μM	23531921
BE2	Growth Inhibition Assay			IC50=0.71 μM	23531921
SY5Y	Growth Inhibition Assay			IC50=0.36 μM	23531921
KCNR	Growth Inhibition Assay			IC50=0.46 μM	23531921
HEK293	Growth Inhibition Assay			IC50=8.67 μM	23531921
ARPE19	Growth Inhibition Assay			IC50=24.38 μM	23531921
RC165N	Apoptosis Assay			IC50=2.083 μM	23942095
DU145	Apoptosis Assay			IC50=3.517 μM	23942095
PC-3	Apoptosis Assay			IC50=1.755 μM	23942095
CWR22Pc	Apoptosis Assay			IC50=0.438 μM	23942095
CWR22Rv1	Apoptosis Assay			IC50=0.482 μM	23942095
DMS114	Growth Inhibition Assay			IC50=0.73 μM	24158701
H1173	Growth Inhibition Assay			IC50=2.39 μM	24158701
H526	Growth Inhibition Assay			IC50=3.08 μM	24158701
GLC4	Growth Inhibition Assay			IC50=1.79 μM	24158701
H82	Growth Inhibition Assay			IC50=1.37 μM	24158701
N592	Growth Inhibition Assay			IC50=0.84 μM	24158701
LAN5	Growth Inhibition Assay			IC50=1.04 μM	23531921
RH18	Growth Inhibition Assay			IC50=1.42 μM	23531921
RH30	Growth Inhibition Assay			IC50=1.25 μM	23531921
RH17	Growth Inhibition Assay			IC50=2.51 μM	23531921
RH28	Growth Inhibition Assay			IC50=4.28 μM	23531921
RH36	Growth Inhibition Assay			IC50=5.37 μM	23531921
RH41	Growth Inhibition Assay			IC50=0.48 μM	23531921
RD	Growth Inhibition Assay			IC50=4.32 μM	23531921
TC32	Growth Inhibition Assay			IC50=3.85 μM	23531921
TC71	Growth Inhibition Assay			IC50=4.33 μM	23531921
Ba/F3	Function assay			Inhibition of Stat5 phosphorylation in mouse Ba/F3 cells expressing TEL-Jak2, IC50 = 0.046 μM.	21138246
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.

Targets

JAK2 ^[1]
(Cell-free assay)

0.26 nM

In Vitro
In vitro	5μM AZD1480 induces G2/M arrest and cell death by inhibiting Aurora kinases. ^[1] AZD1480 is a potent JAK2 inhibitor that can suppress growth, survival, as well as FGFR3 and STAT3 signaling and downstream targets including Cyclin D2 in human multiple myeloma cells. At low micromolar concentrations, AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. ^[2]AZD1480 effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis. ^[3]AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase, and that it is capable of inhibiting STAT3 phosphorylation and tumor growth in a STAT3-dependent manner. AZD1480 inhibits tumor angiogenesis and metastasis in part by affecting the tumor microenvironment. ^[4]
Kinase Assay	kinase assays
Kinase Assay	Inhibition studies of AZD1480 are performed using recombinant Jak1, Jak2, or Jak3 under buffer conditions of 50 mM HEPES pH 7.3, 1 mM DTT, 0.01% Tween-20, 50 mM/ml BSA, and 10 mM MgCl₂. Jak3 enzyme is expressed as N-terminal GST fusion in insect cells and purified by glutathione-affinity and size-exclusion chromatographies. Enzymes are assayed in the presence of AZD1480 (10 point dose response, in triplicate, from 8.3 μM to 0.3 nM in half-log dilution steps) using 1.5 μM peptide substrate (Jak1: FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2 and Jak3: FAM-SRCtide) and screened under their respective ATP Km (Jak1: 55 μM, Jak2: 15 μM, Jak3: 3 μM) and approximated physiological ATP concentration of 5 mM. Phosphorylated and unphosphorylated peptides are separated and quantified by a Caliper LC3000 system for calculating percent inhibition.
細胞実験	細胞株	Renca or 786-O cells, mouse endothelial cells and splenic CD11b⁺/c^-myeloid cells, HUVECs
	濃度	~1 μM
	反応時間	48 or 24 hours
	実験の流れ	Renca or 786-O cells are suspended in DMEM medium with 5% FBS , and seeded in 96-well plates (5×10³ per well) to allow adhesion and then treated with DMSO or AZD1480 for 48 hours. Cell viability is determined by MTS assay. Absorbance at 490 nm is measured with Mikrotek Laborsysteme. Mouse endothelial cells and splenic CD11b⁺/c^- myeloid cells are enriched from tumor-bearing mice,and cultured in 5% FBS RPMI-1640 medium. HUVECs are cultured on collagen 1–coated plates in complete medium. All cells are treated with DMSO and AZD1480 at various doses for 24 hours. Cell viability is determined by counting cell number manually. All the experiments are repeated 3 times.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	p-STAT3 / STAT3 / p-JAK2 / JAK2 p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2		22027691
	Immunofluorescence	pSTAT5		30140255
	Growth inhibition assay	Cell proliferation Cell viability		22027691

In Vivo
In Vivo	AZD1480 inhibits the STAT3 phosphorylation in an xenograft model of human solid tumors and multiple myeloma. ^[1] In vivo, AZD1480 inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial glioblastoma (GBM) tumors by inhibiting STAT-3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by AZD1480 should be considered for study in the treatment of patients with GBM tumors. ^[3]AZD1480 blocks lung infiltration of myeloid cells and formation of pulmonary metastases in both mouse syngeneic experimental and spontaneous metastatic models. Furthermore, AZD1480 reduces angiogenesis and metastasis in a human xenograft tumor model. ^[4] The Jak2 inhibitor, AZD1480, suppresses the growth of human solid tumor xenografts harboring persistent Stat3 activity. ^[5]
動物実験	動物モデル	Female BALB/c and athymic nude (NCR ^- nu/nu) mice (7–8 weeks old)
	投与量	Once a day at the dose of 50 mg/kg or twice daily at 30 mg/kg
	投与経路	Oral gavage

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT01219543	Terminated	Solid Tumour\|Advanced Solid Malignancies\|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma\|EGFR and/or ROS Mutant NSCLC\|Lung Metastasis Carcinoma\|Gastric Cancer	AstraZeneca	November 2010	Phase 1
NCT01112397	Terminated	Solid Malignancies	AstraZeneca	April 2010	Phase 1

参考
[1] E Derenzini, et al. Blood Cancer J, 2011, 1(12), e46. [2] Scuto A, et al. Leukemia, 2011, 25(3), 538-50. [3] McFarland BC,et al. Cancer Ther, 2011, 10(12), 2384-93. [4] Xin H, et al. Cancer Res, 2011, 71(21), 6601-10. [5] Hedvat M, et al. Cancer Cell, 2009, 16(6), 487-97. + 展開

参考

+ 展開

化学情報

分子量	348.77	化学式	C₁₄H₁₄ClFN₈
CAS No.	935666-88-9	SDF	Download AZD1480 SDFをダウンロードする
Smiles	CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 70 mg/mL ( (200.7 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):